Acura Pharmaceuticals, Inc. is a drug delivery company, which engages in the research, development, and commercialization of technologies and products intended to address safe use of medications. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for ACUR. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: ACUR is a Buy candidate.
ACUR stock price ended at $0 on 水曜日, after rising NaN%
On the latest trading day Feb 11, 2026, the stock price of ACUR rose by NaN%, climbing from $0.00 to $0.00. Throughout the session, the stock experienced a volatility of NaN%, with prices fluctuating between a daily low of $0.00 and a high of $0.00. Alongside this price increase, trading volume also rose by 660 shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 160 shares were traded, amounting to a market value of approximately --.